Short-term Efficacy and Safety of Phacoemulsification Associated with iStent inject W® in Patients with Controlled Open-angle Glaucoma.

To evaluate the efficacy and safety of iStent inject W® combined with phacoemulsification in patients with controlled open-angle glaucoma undergoing cataract surgery. We conducted a retrospective, bi-centric study of patients with controlled chronic open-angle glaucoma who underwent phacoemulsification combined with the injection of two iStent inject® W's. Patient characteristics, including IOP and the number of glaucoma medications, were evaluated preoperatively and 1 week, 1 month and 6 months postoperatively. The primary endpoint was IOP reduction, and the secondary endpoint was the reduction in the number of glaucoma medications. In this study, 85 eyes were included. The majority of patients had POAG (85% of eyes). Preoperative mean IOP was 16.1±2.0 mmHg with a mean of 2.3±0.5 glaucoma medications. At one week postoperatively, mean IOP was 16.7±3.1 mmHg with a mean of 2.0±0.7 hypotensive medications. At 1 and 6 months, mean IOP was 14.2±2.1 mmHg and 13.0±1.5 mmHg, with a mean of 2.0±0.6 and 1.8±0.5 glaucoma medications, respectively. The percentage IOP reduction at 1 and 6 months was 11.6% (P=0.001) and 19.3% (P<0.0001), respectively. Regarding glaucoma medications, at 1 and 6 months, the reduction in the number of medications was 12.9% (P=0.025) and 22.4% (P=0.003), respectively. The most frequent significant postoperative adverse events were corneal edema in 7%, IOP spikes in 6%, and hyphema in 6% of eyes, which resolved spontaneously. The iStent inject® W implanted during phacoemulsification effectively reduces IOP and the number of glaucoma medications needed at 6 months of follow-up, with a favorable safety profile, in patients with controlled open-angle glaucoma.

Informations de copyright

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.